On November 9, 2017 OncoSec Medical Incorporated ("OncoSec") (NASDAQ:ONCS), a company developing DNA-based cancer immunotherapies, reported that it will present emerging data from its novel, multi-gene expression platform termed Polycistronic Interleukin-12 Immune Modulator (PIIM) (Press release, OncoSec Medical, NOV 9, 2017, View Source [SID1234521893]). The poster presentation entitled: "Intratumoral administration of a multigene construct by electroporation can effectively modulate anti-tumor response in a murine B16.F10 model" (P403) will be presented during the "Oncolytic Viruses and Intratumoral Therapies" session on Friday, November 10th at 12:30-2:00 p.m and 6:30-8:00 p.m. ET at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) Annual Meeting 2017, in National Harbor, MD.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The PIIM platform builds upon OncoSec’s existing plasmid-based cancer immunotherapy platform and may offer both enhanced therapeutic activity as well as manufacturing efficiencies. Preclinical data demonstrate the novel platform’s flexibility to add multiple immune modulating genes to alter the tumor microenvironment which, when combined with electroporation in a preclinical tumor animal model, resulted in regression of tumor growth in both the treated primary lesion and a distant untreated lesion.

"Immunotherapy has transformed the treatment of multiple cancers, including melanoma; however, current agents do not help all patients or have toxic side effects preventing broader use or in combination with other agents," said Dan O’Connor, CEO of OncoSec. "The ability to enhance response with a simultaneous and potentially safe combination therapy, including cytokines, checkpoint modulators, and antibodies, allows the immune system to better recognize and attack the tumor, an advantage of the PIIM platform versus other products currently under development."

The full abstract is available and can be viewed on the STIC website at www.sitcancer.org. The presentation is available in the Publications section of OncoSec’s website.

About the SITC (Free SITC Whitepaper) Annual Meeting
The Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) is a non-profit medical professional society of influential scientists, academicians, researchers, clinicians, government representatives, and industry leaders from around the world dedicated to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy. Currently, SITC (Free SITC Whitepaper) has nearly 1,600 members representing 17 medical specialties and are engaged in research and treatment of at least a dozen types of cancer. The 32nd SITC (Free SITC Whitepaper) Annual Meeting & Associated Programs will take place November 8-12, 2017 at the Gaylord National Hotel & Convention Center in National Harbor, MD. For more information, please go to View Source

About Polycistronic Interleukin-12 Immune Modulator (PIIM)
PIIM represents an advancement for OncoSec’s plasmid-based cancer immunotherapy platform, coupling improved in vivo electroporation with the ability to combine multiple therapeutic molecules in a single DNA plasmid. The PIIM technology platform offers expedited design and molecular cloning of these molecules, individually or fused, with tailored effector functions and relative expression levels. Delivery of multifunctional combinations from a single plasmid backbone may also simplify the manufacturing process.

Titan Pharmaceuticals has filed a 10-Q – Quarterly report [Sections 13 or 15(d)] with the U.S. Securities and Exchange Commission .

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On November 9, 2017 NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, reported the highlights of numerous advances in understanding immune response and cancer immunotherapy using the nCounter platform that will be presented at the 32nd Annual Meeting of the Society of Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) (Press release, Ligand, NOV 9, 2017, View Source [SID1234521879]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The scope of nCounter-based research being presented at this year’s SITC (Free SITC Whitepaper) conference demonstrates our scientific and commercial momentum in immuno-oncology," said Alessandra Cesano, chief medical officer of NanoString. "In addition, several abstracts outline the unique capabilities of our Digital Spatial Profiling technology to characterize the tumor and its microenvironment to inform cancer research and drug development."

At least 45 abstracts using NanoString’s nCounter platform will be presented at the SITC (Free SITC Whitepaper) Annual Meeting, being held in National Harbor, Maryland, Nov. 8-12, 2017. The research being presented spans a wide breadth of applications including biomarker development, assessing the biology of immune responsiveness and resistance, and digital pathology. They include biomarker studies covering 21therapeutic agents, as single agents or in combination.

Nineteen studies used NanoString’s PanCancer Series of panels to explore biomarkers associated with response to immunotherapy. Fourteen of these studies incorporate NanoString’s best-selling PanCancer Immune Profiling Panel. An additional five studies incorporating both early access and commercial versions of NanoString’s new PanCancer IO 360 Panel. The PanCancer IO 360 Panel assays key pathways from the tumor, the microenvironment and the immune system and includes more than 20 signatures that are potentially associated with therapeutic response to novel therapeutic agents with "matched" mechanisms of action. Three additional studies incorporate the nCounter Hallmarks of Cancer suite of gene expression panels, which includes three panels covering Cancer Immune Profiling, Cancer Pathways, and Cancer Progression.

The PanCancer IO 360 Panel studies provide initial evidence of positive association between the Tumor Inflammation Signature scores and clinical response to different immuno-oncology agents including nivolumab, ipilimumab, pembrolizumab and entinostat. NanoString’s Tumor Inflammation Signature (TIS) was recently described by Ayers, et al. (View Source) and is included in the PanCancer IO360 panel. The Tumor Inflammation Signature measures the presence or absence of a peripherally suppressed adaptive immune response within the tumor.

Five studies cover the use of NanoString’s Digital Spatial Profiling (DSP) platform in immuno-oncology research. DSP allows for digital quantification of protein from discrete regions of FFPE tissue in an automated and multiplex format. DSP will become widely available with the launch of a new instrument planned for late 2018, and in the meantime is available under a Technology Access Program.

Two studies cover the use of 3D Biology panels and demonstrate the utility of the nCounter platform. NanoString’s 3-D Flow technology provides detailed molecular profiles of T cell populations, and enables unique, simultaneous analysis of high-plex protein and RNA data. 3D Biology and 3D Flow approaches can be used to characterize baseline immunological state and response to stimulation, which may be useful for profiling mechanisms of action or therapeutic response.

At the 2017 SITC (Free SITC Whitepaper) Annual Meeting, NanoString will showcase its nCounter platform, IO360 Data Analysis, Digital Spatial Profiling and 3D Biology capabilities at booth #605.

NanoString will host a Digital Spatial Profiling Educational Session on Nov. 11, 2017, 12:45 – 1:45 p.m.

Below is a summary of abstracts co-authored by NanoString employees:

Abstract # Title Hyperlink
05 A dendritic cell targeting NY-ESO-1 vaccine significantly augments early and durable immune responses in melanoma patients pretreated with human Flt-3 Ligand View Source

019 ENCORE-601: Phase 1b/2 study of entinostat (ENT) in combination with pembrolizumab (PEMBRO) in patients with non-small cell lung cancer (NSCLC) View Source

P40 Deep proteomic and transcriptomic analysis of sorted T cells with a simple, integrated workflow View Source

P43 Assessment of Pharmacodynamic Effects of Immuno-Oncology Agents in Cynomolgus Monkeys using High-Content Gene Expression Profiling View Source

P64 Analytical Validation of Digital Spatial Profiling – a novel approach for multiplexed characterization of protein distribution and abundance in FFPE tissue sections View Source

P65 Spatially-resolved, multiplexed digital characterization of protein abundance in FFPE tissue sections: application in preclinical mouse models View Source

P66 Digital spatial profiling platform allows both spatially-resolved, multiplexed measurement of solid tumor and immune-associated protein distribution and abundance using a single FFPE tissue section View Source

P72 Analysis of biomarkers from a cohort of advanced melanoma patients previously exposed to immune checkpoint inhibition treated with entinostat (ENT) and pembrolizumab (PEMBRO).

View Source
P73 First-in-human neoadjuvant study of the immunogenomic impact of the oral IDO inhibitor epacadostat (INCB024360) on the tumor microenvironment of advanced ovarian cancer View Source

P98 Immunological profiling of baseline and resected biopsies from locally/regionally advanced/recurrent melanoma treated with neoadjuvant combination ipilimumab (3mg/kg or 10mg/kg) and high dose IFN-α2B View Source

P99 Biomarker analysis from the OpACIN trial (Neo-/adjuvant ipilimumab + nivolumab (IPI+NIVO) in palpable stage 3 melanoma) View Source

P100 Pretreatment gene expression correlation with clinical response to pembrolizumab or nivolumab in metastatic melanoma View Source

P383 Molecular and immune characterization of melanoma metastases with heterogeneous PTEN expression View Source

P485 Use of the NanoString Gene Expression Profiling Platform to Capture the Immunological Status of the Leukemia Microenvironment View Source

P512 Deep immunoprofiling of rare T-cell populations from clinical samples View Source

P524 Clinical and biomarker analyses of a phase II study of intratumoral tavokinogene telseplasmid (pIL-12) plus pembrolizumab in stage III/IV melanoma patients predicted to not respond to anti-PD-1 View Source

BioTime has filed a 10-Q – Quarterly report [Sections 13 or 15(d)] with the U.S. Securities and Exchange Commission (Filing, 10-Q, BioTime, 2017, NOV 9, 2017, View Source [SID1234521845]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Genomic Health has filed a 10-Q – Quarterly report [Sections 13 or 15(d)] with the U.S. Securities and Exchange Commission (Filing, 10-Q, Genomic Health, 2017, NOV 9, 2017, View Source [SID1234521911]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!